



A systematic review and meta-analysis of the use of drug-coated balloon angioplasty for treatment of both de novo and in-stent coronary chronic total occlusions

Rajkumar Natarajan^{1,2}  · Natasha Corballis^{1,2} · Ioannis Merinopoulos^{1,2} · Vasiliki Tsampasian^{1,2} · Vassilios S. Vassiliou^{1,2} · Simon C. Eccleshall¹

Received: 14 November 2024 / Accepted: 17 March 2025 / Published online: 10 April 2025
© Crown 2025

Abstract

Background Modern contemporary percutaneous coronary intervention (PCI) techniques with drug-eluting stents (DES) have high procedural success rates in chronic total occlusion (CTO) but with a high prevalence of repeat revascularization. The use of drug-coated balloons (DCBs) in CTO is an alternative treatment strategy. The evidence for DCBs in CTO is, therefore, of interest, and we provide a structured and comprehensive review of the evidence available in terms of the use of DCBs in CTO, including de novo and in-stent (IS) CTO lesions.

Objectives We conducted a systematic review and meta-analysis on the use of DCBs in the management of coronary CTO.

Methods Electronic databases (PubMed, Embase and Ovid) were systematically searched from inception to April 2024 for DCB CTO studies. A meta-analysis was undertaken using a random-effects inverse-variance method due to heterogeneity. The primary outcome is target lesion revascularization (TLR). Secondary outcomes are major adverse cardiac events (MACE) as a composite of target lesion revascularization (TLR), cardiac death (CD), and any myocardial infarction (MI) including procedural and non-procedural MI, target vessel revascularization (TVR), angiographic outcomes such as late lumen loss (LLL), binary restenosis, and reocclusion.

Results A total of 10 studies consisting of 1,695 patients were systematically reviewed. This showed that late luminal changes in terms of lumen gain and minimal lumen loss were consistently seen in CTO cohorts 7–12 months after DCB treatment. Five studies were included for meta-analysis with 1,474 patients. There were no significant differences in TLR between treatment strategies such as DCB, DES, and hybrid (DES + DCB) in both de novo and IS-CTO populations as follows: DCB vs DES [OR, 0.71; 95% CI 0.49–1.02], DCB vs DES in IS-CTO [OR, 0.78; 95% CI 0.45–1.34], DCB vs Hybrid [OR, 0.96; 95% CI 0.39–1.43], and hybrid vs DES [OR, 0.76; 95% CI 0.15–3.84]. Similar findings were seen with the MACE outcome. A sensitivity analysis showed no difference between the above-mentioned groups in terms of MI, CD, and TVR.

Conclusion The limited initial evidence on DCB in coronary CTO-PCI suggests a safe and effective alternative treatment strategy and suggests RCTs are, therefore, required.

Vassilios S. Vassiliou and Simon C. Eccleshall contributed equally.


✉ Rajkumar Natarajan
r.natarajan@uea.ac.uk

¹ Department of Cardiology, Norfolk and Norwich University Hospital, 2.06 Bob Champion Research and Education Building, Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK

² Norwich Medical School, University of East Anglia, Norwich, UK

Graphical Abstract

A systematic review and meta-analysis of the use of drug coated balloon angioplasty for treatment of both de novo and in-stent coronary chronic total occlusions.



Keywords Drug coated balloon · Chronic total occlusion · Drug eluting stent · Percutaneous coronary intervention · CTO PCI

Introduction

A chronic total occlusion (CTO) is a complete occlusion of the coronary artery, with TIMI 0 flow through the lesion, but no evidence of thrombus, no staining at the proximal cap, and presence of mature collaterals with definitive corroborating evidence of occlusion duration ≥ 3 months as defined by the CTO-ARC consortium [1]. The prevalence of CTO varies from 15 to 20% of the patients undergoing coronary angiography [2–4] and higher incidence is found in patients with history of CABG [4]. CTO-PCI is a technically challenging procedure requiring additional skill sets and carries higher procedural risks [5, 6]. In the 2021 ACC/AHA [7] guidelines, CTO-PCI carries a class II-b/ level B evidence of recommendation, whereas in the 2019 ESC guidelines [8], CTO-PCI with a class II-a/ level B evidence is recommended for patients with refractory angina symptoms or with a large area of documented ischemia in the territory of the occluded vessel. The use of viability testing is heavily supported in the guidelines.

Technical and technological advances in coronary intervention have led to a much-improved success rate in CTO-PCI procedures in the past decade, dominated by the use of second- and third-generation DES and intravascular

imaging techniques. Nevertheless, restenosis and stent failure (SF) remain high at 14–30% [5–7] in this unique subset of coronary lesions due to increasing lesion length, heavy calcification, lesion location (such as aorto-ostial or bifurcations), increased negative remodeling post-procedure, in-stent occlusions (IS-CTO), and stent factors including thickness, number, and design [8]. Furthermore, the adoption of aggressive algorithms to re-enter true lumen from the subintimal space predisposes to stent under-expansion and malapposition.

A meta-analysis comparing medical therapy and PCI in randomized studies for CTO showed no benefit in cardiac intervention [9]. It could be that the presence of the metallic stent limited the benefit from intervention for the reasons outlined above. Drug-coated balloons offer an alternative ‘no-metal’ local drug delivery strategy via a semi-compliant balloon technology [10] which could mitigate stent-related complications in CTO lesions. In de novo CTO lesions, DCB strategy may preserve coronary vasomotion, induce positive vessel remodeling, prevent stent-related complications, and reduce DAPT duration. While there are emerging evidence on use of DCBs in other subsets [11–13] of coronary lesions, including cost-effectiveness and mechanistic studies [14–16], the evidence on DCB in CTO remains scarce.

In this work, we sought to systematically review the available literature on use of DCB in coronary CTO lesions including de novo and IS-CTO.

Methods

The study was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement. Electronic databases, including PubMed, Embase, and Ovid, were comprehensively searched from inception until April 16th, 2024, using the MeSH terms “(drug-coated balloon OR DCB OR DEB OR drug-eluting balloon) AND (chronic total occlusion OR CTO) AND (percutaneous coronary intervention)”. Clinical studies that assessed the use of DCB for the treatment of chronic total occlusion were included. Any study design was included. We excluded studies with incomplete data, no access to key data, and case reports only.

The primary outcome was target lesion revascularization (TLR). The secondary outcomes include major adverse cardiac events (MACEs) as a composite of target lesion revascularization (TLR), myocardial infarction(MI), cardiac death(CD). Other secondary outcomes were TVR, angiographic follow-up measures including late lumen loss, binary restenosis, late lumen gain, and reocclusion.

Two independent researchers (RN and NC) screened the abstracts individually, reviewed the full-text articles, and conflicts were resolved after discussion with a third researcher (VSV). Data were extracted from the included studies after full-text review and entered into a structured Excel spreadsheet comprising publication details, study design, baseline patient characteristics, procedural details, and outcomes. The study details that were extracted included: author, study design, year of publication, intervention, and sample size. The extracted baseline patient characteristics included age, sex, hypertension, diabetes, dyslipidemia, smoking, MI, previous PCI, prior CABG, clinical presentation, and LVEF. Procedural details that were extracted are as follows: access site, coronary artery intervened, J-CTO score (blunt stump, calcification, angulation, length > 20 mm and retry lesion), syntax score, DCB profile, DES profile, dissection types, and bailout stenting rates. Clinical outcomes that were available included: major adverse cardiovascular outcomes, TLR, MI, CD, target vessel revascularization, all-cause death, and angiographic outcome measures included reference vessel diameter, diameter stenosis %, late lumen loss, binary restenosis rate, reocclusion, and late lumen gain. The quality of the studies included for meta-analysis was assessed using the Newcastle–Ottawa scale [17]. Our study was registered with PROSPERO and the registration number is CRD42024569341.

Statistical analysis

Statistical analysis was performed using the Review Manager software version 5.4 (The Nordic Cochrane Centre, Copenhagen, Denmark) on macOS software. Statistical heterogeneity was assessed by Chi-squared test (Cochrane Q) and I^2 statistic test. In view of the differences in study designs, intervention arms, and outcome measures, a random-effects inverse-variance pooling model was used for all the meta-analyses independently of heterogeneity. Odds ratios (ORs) were reported with 95% confidence intervals (CIs). $P < 0.05$ was considered statistically significant. Sensitivity analysis was performed to obtain ORs for each of the MACE components, outcomes such as CD and MI.

Results

Study characteristics

After screening 4079 studies, 10 clinical studies were identified for inclusion. For the five studies with a comparator arm [18–22], we have conducted a meta-analysis. The other five studies were single-arm studies [24–28] and have been discussed in a systematic review. Two of the five comparative studies exclusively compared DCB vs DES in in-stent-CTO population [21, 22]. For the studies included in the meta-analysis, there was significant methodological heterogeneity and as such, these have been grouped accordingly: (1) DCB vs DES, (2) DCB vs DES in IS-CTO, (3) DCB vs hybrid, and (4) hybrid vs DES. Figure 1 represents the PRISMA flowchart for study selection. Figure 1 represents the search strategy as per PRISMA guidelines.

The Newcastle–Ottawa scale (NOS) quality assessment of the five studies included for meta-analysis ranked 3 as high-quality studies and 2 as moderate quality, as shown in Table 1.

Baseline clinical characteristics

Of the total 1695 patients from 10 studies, 65.7% were male with the mean age of 63.1 (IQR 58.3–69.8). Hypertension was highly prevalent (55.5%), followed by diabetes (34.6%). It is not uncommon for the studies to include a high number of CTO patients with prior PCI or CABG and was particularly notable in the studies with a hybrid (DCB + DES) arm. Table 2 below summarizes the study designs and baseline characteristics.




Fig. 1 Search strategy

Table 1 Summaries the Newcastle–Ottawa scale for quality assessment

Study	Selection	Comparability	Outcome	Total	Quality
Basavarajaiah et al. [21]	***		***	6	Moderate
Zhang et al. [22]	***	***	***	8	High
Wang et al. [18]	****	**	**	8	High
Qin et al. [19]	****		***	6	Moderate
Madanchi et al. [20]	****	*	***	8	High

Angiographic characteristics

The summary of the angiographic characteristics of 1406 lesions is provided in Table 3. One of the studies [21] did not provide details of the target vessel. Of the other 9 studies, most CTO lesions involved right coronary artery (RCA, 39%) followed by left anterior descending artery (LAD) at 37.6%. The length of the DCB was 22.7 to 60 millimetres (mm) and the diameter range was from 2.0 to 3.5 mm indicating that target vessels included the whole range of small to large sized coronary vessels. Hybrid strategy involved DES and DCB implantation either as an initial planned strategy (Wang et al. [18]) or as a bailout strategy in cases of flow limiting dissections and threatening abrupt vessel closure (Madanchi et al. [20]) or both (Qin et al. [19]).

Systematic review

Single-arm studies with DCB-only strategy

A total of five single-arm studies is shown in Table 4 as below.

A feasibility study, conducted by Scheller et al. [23] in 2016, was a multi-center cohort study of 34 patients with de novo CTO recanalized and treated with DCB-only strategy (SeQuent, B. Braun, Germany). Satisfactory recanalization (visual residual stenosis of less than 30% without major dissection) was achieved in 27(79.4%) of patients. Of the 27 patients, restenosis and reocclusion occurred in only 1 patient (3.7%). In the unsatisfactory group of seven

Table 2 Summary of study designs and baseline characteristics

First author/study/ references	Year	Study design	Intervention (n)	Sample size	Age	Male n(%)	Smoking n(%)
Scheller et al. [23]	2016	Prospective feasibility study	DCB only (34)	34	59.18 ± 12.76	26(76.5)	5(14.7)
Onishi et al. [24]	2018	Prospective observational study	DCB only (12)	12	72 ± 6	5(45)	7(64)
Basavarajaiah et al. [21]	2021	Retrospective observational study	DCB(113) v DES(198) v POBA(88) in ISR CTO	403	69 ± 9.6	333(83.5)	153(38)
Onishi et al. [25]	2020	Retrospective observational study	DCB only (20)	20	72 ± 6	6(60)	6(60)
Jun et al. [26]	2022	Retrospective observational study	DCB only (84)	84	56.1 ± 9.9	72(85.7)	16(19.0)
Zhang et al. [22]	2022	Retrospective observational study	DCB (78) v DES (136) in IS-CTO	214	57.8 ± 9.0	179(83.6)	68(31.8)
Wang et al. [18]	2023	Prospective observational study	DCB (140) v hybrid (141) v DES(310)	591	58.4 ± 10.9	207(73.7)	110(39.9)
Qin et al. [19]	2023	Retrospective observational study	DCB (97) v hybrid (57)	154	60.2 ± 12.2	133 (86.4)	35 (22.7)
Terashita et al. [27]	2023	Retrospective observational study	DCB only (71)	71	67.7 ± 11.2	54(76.1)	23(32.4)
Madanchi et al. [20]	2024	Prospective observational study	DCB (46) vs hybrid (66) vs DES (43)	112	66 ± 10	100(89)	24(22)
First author/study/ reference	DM n (%)	HTN n (%)	Dyslipidemia n (%)	Previous MI n (%)	Previous CABG n (%)	LVEF n (%)	Prior PCI n (%)
Scheller et al. [23]	8(23.5)	25(73.5)	19(55.9)	ND	ND	ND	ND
Onishi et al. [24]	6(55)	7(64)	6(55)	2(18)	ND	ND	4(36)
Basavarajaiah et al. [21]	201(50.4)	319(79.9)	ND	ND	24(6)	ND	404(100)
Onishi et al. [25]	4(40)	4(40)	6(60)	2(20)	ND	ND	5(50)
Jun et al. [26]	32(38.1)	49(58.3)	40(47.6)	21(25)	ND	50 ± 12.9	21(25)
Zhang et al. [22]	94(61.5)	134(62.6)	163(76.2)	113(52.8)	10(4.6)	62(58,66)	ND
Wang et al. [18]	105(37.4)	154(54.8)	150(53.4)	39(13.9)	4(1.4)	58.2 ± 7.0	39(13.9)
Qin et al. [19]	52(33.8)	100(64.9)	22(14.3)	43(27.9)	1(0.6)	59.4 ± 9.3	77(50)
Terashita et al. [27]	32(45.1)	57(80.3)	57(80.3)	26(36.6)	ND	55.7 ± 9.4	41(57.7)
Madanchi et al. [20]	38(35)	92(84)	88(79)	46(41)	11(10)	53 ± 10	ND

DCB drug-coated balloon, DES drug-eluting stent, POBA plain old balloon angioplasty, IS-CTO in-stent chronic total occlusion, DM diabetes mellitus, HTN hypertension, LVEF left ventricular ejection fraction, MI myocardial infarction, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, ND not disclosed. Data are mean (standard deviation), median (interquartile range), or number (percentage), as appropriate

patients who were left for evaluation after DCB treatment, three had restenosis and one had reocclusion at follow-up. Significant reduction in Canadian cardiovascular society (CCS) angina class was observed. No death or MI was seen. Late luminal enlargement (LLE) was found in 23

(67.6%) of the patients with a mean late luminal gain of 0.11 ± 0.49 mm at 8.62 ± 9.33 months of follow-up.

Corroborating the above result, Onishi et al. [24] demonstrated a late lumen loss of -0.13 ± 0.61 mm at 7.7 ± 2.8 months post DCB angioplasty in 12 CTO patients

Table 3 Summary of lesion characteristics of all studies

First author/study/references	LAD n (%)	LCx n (%)	RCA n (%)	J-CTO	DCB length (mm)	DCB diameter (mm)
Scheller et al. [23]	16(47.1)	5(14.7)	13(38.1)	ND	25.60±6.20	2.55±0.42
Onishi et al. [24]	5(42)	1(8)	6(50)	ND	23.75±5.69	2.38±0.2
Basavarajaiah et al. [21]	ND	ND	ND	ND	48.12±25.7	ND
Onishi et al. [25]	5(45)	1(9)	5(45)	ND	22.7±6.1	2.3±0.3
Jun et al. [26]	45(48.4)	24(25.8)	24(25.8)	1.4±0.6	42.3±17.1	2.7±0.4
Zhang et al. [22]	87(41)	26(12)	101(47)	2(1,3)	30(30,60)	3.00(2.50,3.5)
Wang et al. [18]	115(39.7)	59(20.3)	116(40)	1.79±1.07	35.8±19.9	2.63±0.38
Qin et al. [19]	48(31.2)	70(45.5)	36(23.4)	1.5±1.3	30±13.2	2.3±0.3
Terashita et al. [27]	25(30.5)	26(31.7)	31(37.8)	1.7±0.9	47.1±19.7	2.78±0.43
Madanchi et al. [20]	32(29)	22(20)	59(53)	1.8±0.7	ND	2.76±0.51

DCB drug-coated balloon, LAD left anterior descending, LCx left circumflex, RCA right coronary artery, J-CTO Japanese chronic total occlusion score, mm millimetre, ND not disclosed. Data are mean (standard deviation), median (interquartile range), or number (percentage), as appropriate

Table 4 Summary of DCB-only single arm studies and follow-up (f/u) angiographic outcomes

First author/study/references	Lesion (n)	CTO type	RVD, mm at f/u	Late lumen loss, mm at f/u(months)	Binary restenosis n (%)	Reocclusion rate n (%)
Scheller et al. [23]	34	De novo	2.21±0.58	ND	6(17.6)	2(5.9)
Onishi et al. [24]	12	De novo	2.18±0.53	−0.13±0.61 (7.7±2.8)	2(17)	ND
Onishi et al. [25]	20	De novo	2.49±0.39	−0.45±0.27 (7.2±2.5)	ND	ND
Jun et al. [26]	84	De novo	2.5±0.7	0.03±0.53 (6)	10(14.9)	2(3)
Terashita et al. [27]	82	71de novo and 11 IS-CTO	3.0(2.4–3.2)	−0.15(IQR 0.4 to 0.23 mm) (8.7±3.9)	12(16.9)	3(4.2)

DCB drug-coated balloon, J-CTO Japanese chronic total occlusion score, RVD reference vessel diameter, mm millimetre, f/u follow-up, ND not disclosed. Data are mean (standard deviation), median (interquartile range), or number (percentage), as appropriate

in a single-center observational study, restenosis was seen in 2 patients (17%). The same group also showed that LLE following DCB angioplasty occurred more frequently in CTO lesions in their search for predictors of LLE after DCB in de novo coronary artery disease in a retrospective observational study in 2020 [25]. The late lumen loss in the CTO group was $−0.45±0.27$ mm at $7.2±2.5$ months and no TLR was seen in this particular CTO group with LLE at $8±2.7$ months of clinical follow-up. Though the vessel size in these three studies was ≤ 2.5 mm, the results clearly demonstrated positive remodeling occurring in small-sized CTO vessels when treated with DCB.

In a retrospective observational study evaluating the long-term clinical outcomes of DCB-only strategy for de novo CTO ($n=84$), Jun et al. [26] found low rates of hard endpoints and acceptable MACE (composite of CD, non-fatal MI, TVR and TV thrombosis) rates of 8.3% at 1 year and 16.7% at 2 years of follow-up, with a minimal mean late lumen loss of $0.03±0.53$ mm at 6 months ($n=61$). This study reaffirms the efficacy of DCB in inhibiting negative

remodeling in CTO lesions with 55.2% lesions with positive late lumen gain.

Terashita et al. [27] assessed the efficacy of DCB treatment following IVUS guided successful intraplaque wiring and lesion preparation with cutting or scoring balloons in de novo CTO lesions. J-CTO score ≥ 2 was seen in 44 lesions (53.7%) and retrograde procedures were undertaken in 23 (28%) of the 84 lesions. At a median follow-up of 29 months, TLR occurred in 10 (12%) out of 82 lesions. Of the 64 lesions (57 patients) followed up angiographically, 37 (57.8%) exhibited late lumen enlargement and overall, the late lumen loss (LLL) was $−0.15$ mm (IQR $−0.4$ to 0.23 mm) at 9 months.

DCB vs DES in de novo CTO

Wang et al. [18] conducted a prospective observational study in China, reporting no significant difference in cumulative MACE (composite of all-cause death, TVR and non-fatal MI) at 3 years between DCB strategy ($n=290$)

and DES strategy ($n=310$) in de novo CTO patients and a significant negative late lumen loss was seen in DCB group (-0.08 ± 0.65 mm vs 0.35 ± 0.62 mm, $p < 0.001$). The DCB strategy cohort included both DCB only ($n=143$) and hybrid (DES + DCB, $n=147$), and their LLL outcomes were reported together. This study demonstrated that DCB can be safely used as an adjunct or definitive treatment for CTO but was a non-randomized observational study.

DCB vs DES in de novo and IS-CTO

Madanchi et al. [20] conducted a prospective single-center observational study in a small population of CTO patients from their prospective registries comparing successful CTO-PCI with DCB vs DES. The primary endpoint, MACCE (a composite of CD, TLR, target vessel-MI and stroke) at 12 months, was observed at a rate of 26% in DES group vs 11% in DCB group and cumulative stent length seemed to predict MACCE strongly (HR 1.15 [1.05, 1.26] per 10 mm, $p=0.003$). The DCB group ($n=46$) included 13 (28%) IS-CTO patients. This is the first prospective study to show a promising better long-term outcome in a DCB-only group with TLR rates of 8% compared to 26% with DES in subgroup analysis and of note, no acute vessel closure was seen in any subgroups.

DCB vs DES in IS-CTO

Basavarajaiah et al. [21] performed the first retrospective multi-center observational analysis on long-term outcomes following IS-CTO recanalization with DCB ($n=91$) vs DES ($n=172$) vs POBA ($n=79$). Though the TLR and TVR rates were generally high across three groups, the overall MACE rate (composite of CD, TLR, TV-MI) was numerically lower in DCB group at 34.1% as compared to 44.8% in DES group and 52% in POBA group ($p=0.05$). An antegrade approach was used in 98.5% of the procedure and 21% of the ISR were in previously placed BMS.

Zhang et al. [22] explored the long-term outcomes of DCB ($n=78$) vs DES treatment ($n=136$) for IS-CTO and observed no significant difference in MACE at a median follow-up of 3 years (28.2% in DCB vs 26.5% in DES group) similar to the previous study by Basavarajaiah et al. [21].

DCB vs hybrid

Qin et al. [19] conducted a retrospective study looking at clinical outcomes between DCB only ($n=97$) and hybrid (DES + DCB) group ($n=57$) in de novo CTO patients. The J-CTO score was higher in hybrid group at 2.0 ± 1.4 compared to DCB-only group at 1.2 ± 1.2 . This was associated with greater procedural complexity as evidenced by more frequent retrograde approach, a greater number of

CTO wires and a longer procedural time and yet the MACE rate (composite of CD, TVR, TV-MI) was comparable between the groups (13% in DCB vs 12% in hybrid).

Meta-analysis

Five studies consisting of 1474 patients were included for meta-analysis [18–22].

Target lesion revascularization (TLR)

There were no significant differences in target lesion revascularization in all the four groups, namely DCB vs DES [OR, 0.71; 95% CI 0.49–1.02], DCB vs DES in IS-CTO [OR, 0.78; 95% CI 0.45–1.34], DCB vs hybrid [OR, 0.96; 95% CI 0.39–1.43], and hybrid vs DES [OR, 0.76; 95% CI 0.15–3.84], as shown in Fig. 2.

Major adverse cardiac outcomes (composite of TLR, MI, and CD)

There were no significant differences in major adverse cardiac events in all the four groups, namely DCB vs DES [OR, 0.74; 95% CI 0.48–1.15], DCB vs DES in IS-CTO [OR, 0.76; 95% CI 0.44–1.33], DCB vs Hybrid [OR, 0.96; 95% CI 0.54–1.69], and Hybrid vs DES [OR, 0.69; 95% CI 0.24–1.99]. A summary of these results is reported in Fig. 3.

Cardiac death (CD)

There was no significant difference in cardiac death after DCB and DES strategies in both de novo and IS-CTO population from four studies as depicted in Fig. 4.

Myocardial infarction (any procedural and non-procedural MI)


An odds ratio of 1.02; 95% CI, 0.50–2.08 was obtained suggesting no significant difference in MI in CTO lesions between DCB and DES strategies. This is illustrated in Fig. 5.

Target vessel revascularization (TVR)


TVR outcomes were available for only three comparative studies and meta-analysis yielded an OR of 0.67; 95% CI [0.44–1.02]. Though there is no statistical significance, the trend seemed to be in favor of DCB in both de novo and IS-CTO population. Figure 6 illustrates these findings.

Forest plots for TLR


A. DCB vs DES



B. DCB vs DES in IS-CTO



C. DCB vs Hybrid



D. Hybrid vs DES




Fig. 2 panels A-D: Forest plots for the TLR outcomes in four different groups of comparisons as described. DCB, drug-coated balloon; DES, drug-eluting stent, Hybrid=DES+DCB strategy, CI, confidence interval; IV, inverse-variance pooling method





Forest plots for MACE**E. DCB vs DES****F. DCB vs DES in IS-CTO****G. DCB vs Hybrid****H. Hybrid vs DES**

Fig. 3 panels E–H: Forest plots for the MACE outcomes in four different groups of comparisons as described. DCB, drug-coated balloon; DES, drug-eluting stent, Hybrid = DES + DCB strategy, CI, confidence interval; IV, inverse-variance pooling method




Fig. 4 Forest plots for the CD outcomes between DCB vs DES arms in four comparative studies. DCB, drug-coated balloon; DES, drug-eluting stent, CI, confidence interval; IV, inverse-variance pooling method




Fig. 5 Forest plots for MI between DCB vs DES arms in four comparative studies. DCB, drug-coated balloon; DES, drug-eluting stent, CI, confidence interval; IV, inverse-variance pooling method




Fig. 6 Forest plots for TVR between DCB vs DES arms in CTO studies. DCB, drug-coated balloon; DES, drug-eluting stent, IS-CTO, in-stent restenosis, CI, confidence interval; IV, inverse-variance pooling method

Discussion

This is the first systematic review and meta-analysis of DCB CTO studies, including research conducted up to April 2024. The meta-analysis consisted of a total of 1474

patients from 5 comparative studies. The important finding of this study was that there were no significant differences in outcomes (TLR, major adverse cardiac events, CD, MI and TVR) between treatment strategies such as DCB, DES, and hybrid in both de novo and IS-CTO population.

First, this shows DCB-only and hybrid strategies are likely to be a safe and effective therapy in treating both de novo and IS-CTO compared to a DES strategy. Second, TLR rates are comparable between the DCB and DES group. Third, the systematic review of all studies shows that late lumen enlargement is consistently seen across the CTO cohort in 7–12 months following DCB treatment.

One of the most beneficial outcomes of drug-coated balloon in de novo coronary artery disease is late lumen enlargement which occurs frequently at 50–74% during early follow-up phase of intervention [28–30] and the possible mechanisms being either vessel enlargement or regression of plaque or healing of dissection flaps or a combination [31, 32]. Scheller et al. [23] first observed a significant increase in mean lumen diameter from 2.08 ± 0.33 mm to 2.19 ± 0.69 mm at 4–8 months of follow-up post DCB and 67.6% of CTO patients showed late lumen gain due to increased vessel size. In studies conducted by Onishi group [24, 25], LLE occurred frequently in small vessel CTO lesions with moderate length of 16–18 mm that were successfully crossed through true lumen via guidewire and adequately dilated. Jun et al. [26] demonstrated late lumen gain in 55.2% of their patients and minimal late lumen loss (0.03 ± 0.53 mm). Comparing to DES group in a study conducted by Wang et al. [18], LLL was better in DCB group (-0.08 ± 0.65 mm vs. 0.35 ± 0.62 mm, $p < 0.001$) and it was attributed to enlarged minimum lumen diameter (MLD) in 60.7% of the DCB patients. This phenomenon is crucial particularly in CTO for the following reasons. First, the actual size of the occluded vessel is often unclear angiographically due to extensively disrupted vessel wall architecture, and it is not uncommon to give less attention to stent optimization after a lengthy and onerous procedure leading to under or over expansion [33]. Second, the chronically hypoperfused negatively remodeled small distal vessel of CTO after DES implantation revascularization often undergoes positive luminal gain [34], leading to late acquired stent malapposition. These mechanisms with a stent in situ potentially give rise to late stent thrombosis, in-stent restenosis and target vessel revascularization [35–37]. These can be averted using DCB to deliver the cytostatic drug to freshly opened CTO allowing luminal increase throughout the length of the vessel, thus overcoming the stent-related adverse events.

Furthermore, the rates of TLR and TVR in the DCB-only group are similar to DES group in the above studies. In the recent studies by Jun et al. and Madanchi et al., TLR rates in DCB-only group are 7.1% and 8%, respectively, at 1-year follow-up. At 2-year follow-up, TLR rates were 11% in Jun et al.'s study. Similar rates of TLR and TVR after CTO-PCI with DES are observed in recent registries and RCT [6, 38–41]. In EURO-CTO [41] and PRISON-IV trial [39], 3-year TLR rate of 7%–11.5% was observed in DES CTO

group, whereas in J-cypher study, a slightly higher TLR rate of 20.7% was seen at 5 years. TVR is a preferred endpoint to assess patency as per CTO-ARC consortium [1]. TVR rate in Madanchi et al. study was 0% in DCB vs 2.3% in DES group at 1 year, whereas Jun et al. reported an incidence of 11% TVR at 2 years in DCB group. This is comparable with recent CONSISTENT-CTO trial [6] in which TVR rate in DES CTO cohort was 7.1% at 1 year and by 2 years, it increased to 11.9%. In the IS-CTO studies by Basavarajaiah et al. and Zhang et al., TLR rates in DCB group were higher around 33% (42.2% in DES group) and 21.8% (19.9% in DES group), respectively, during long-term follow-up of 4 years. IS-CTO, accounting for 5%–25% of all CTO lesions [42], is generally a very challenging subset to treat percutaneously due to the stent-induced fibrous hyperplasia, multiple layers of overlapping long stents, and higher incidence of balloon undilatable or uncrossable lesions [43]. Although the success rates are now similar to that of de novo CTO-PCI, IS-CTO is associated with higher lesion failure and independently associated with TVR [44]. In a study by Lee et al., DES ISR CTO had significantly worse outcomes of MI [HR: 9.71; 95% CI 2.06–45.81; $p = 0.004$] and TLR [HR: 3.04; 95% CI 1.59–5.81; $p = 0.001$] compared to de novo CTO at 5 years [45]. Multiple stent layers are strong predictors of future repeat revascularization [46] irrespective of the treatment strategy. With these considerations, perhaps PCI in this subset should be undertaken only if it is absolutely indicated as adding more stent layers may increase future failure rates. DCB may, therefore, have a pragmatic benefit by precluding further metal deployment in this challenging IS-CTO population.

While Terashita et al.'s study [27] focused exclusively on lesions recanalized by intraplaque wiring, Qin et al.'s study [19] included two lesions (2.1%) that were recanalized by subintimal tracking subsequently treated with DCB, and five lesions (8.8%) in the hybrid group (DES and DCB). The remaining studies did not provide sufficient technical details to draw any conclusions regarding the outcomes of DCB treatment after successful subintimal tracking and re-entry. There is a concern that DCB application in subintimal recanalization may result in excess enlargement and aneurysm of the vessel wall [47]. Given the abundance of specific binding microtubule in subintimal and adventitial layers, ex vivo studies have shown excess retention and delayed clearance of hydrophobic paclitaxel from these layers [48, 49]. Despite this being a limitation, the novel concept of using DCB after plaque modification (PM) either subintimally or intraplaque or both in failed CTO cases is performed as an investment procedure and is increasingly reported to result in a successful staged procedure [50, 51]. Theoretically, DCB promotes vessel healing in PM-CTO segments and dissection planes enabling distal wiring during staged procedure [52]. IMPROVED CTO (NC05158686) is

a multicenter prospective registry investigating this strategy [53].

Finally, DCB is increasingly used as an adjunct in a hybrid approach with DES in resistant acute recoil scenarios and complex procedures involving subintimal tracking and re-entry where a metallic scaffold is needed to maintain patency and adequate distal perfusion. These outcomes are no different to DES-only strategy according to our study.

In a meta-analysis of 17 studies comparing PCI and medical therapy for CTO, Li et al. [9] demonstrated a higher risk of all-cause mortality, cardiac death, and MI with medical therapy compared to PCI strategy with DES. Our work showed CTO-PCI with DCB has no significant differences in similar outcomes when compared to DES strategy. It is reasonable to assume that patients with CTO and reversible ischemia could benefit from revascularization using a DCB strategy compared to medical therapy. However, a randomized controlled trial is necessary to confirm this assumption.

Limitations

Our study has few limitations. First, there are only a few studies in the field with relatively small numbers of patients included. Second, since there are no available randomized controlled trials (RCTs), our study has only included observational studies. Third, there is significant heterogeneity in study methodology and statistical heterogeneity. To address these issues, we conducted several subgroup meta-analyses and used a random effects model to account for the statistical heterogeneity. Current guidelines recommend CTO-PCI primarily for symptom benefit, and this clinical outcome was not measured in any of the studies except one. Larger studies with adequate power and consensus-based uniform safety endpoints are needed to compare each distinct treatment strategy (DCB only, DES only, hybrid) in both de novo and IS-CTO groups individually.

Conclusion

Current evidence suggests that DCB may be a safe and effective alternative or an adjunct to DES in treating coronary CTO, including de novo and IS-CTO lesions. There is a consistent pattern of late lumen gain in CTO lesions after DCB angioplasty, and acceptable rates of hard end points are observed.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00392-025-02639-y>.

Funding We received no funding for this systematic review and meta-analysis. Prof. Vassiliou reports speaker fees from Medtronic and Daichii-Sankyo and receives investigator-initiated research grants. Dr. Eccleshall received speaker fees and acts as a consultant for B Braun and received investigator-initiated research grants. Dr. Merinopoulos has received research grants from Cordis. The funders had no role in study design, data collection, analysis, decision to publish, or manuscript preparation.

Data availability All data supporting the finding of this study are available within the paper and its supplementary information.

Declarations

Conflict of interest Vassiliou reports speaker fees from Sanofi and Daichii-Sankyo and received grants for investigator-initiated research from B Braun and Medtronic. Simon Eccleshall received speaker fees and acts as a consultant for B Braun, Medtronic, Cordis and MedAlliance, and received grants for investigator-initiated research from B Braun. The other authors have nothing relevant to declare.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

- Ybarra LF, Rinfrat S, Brilakis ES, Karmaliotis D, Azzalini L, Grantham JA, Kandzari DE, Mashayekhi K, Spratt JC, Wijeyesundara HC, Ali ZA, Buller CE, Carlino M, Cohen DJ, Cutlip DE, De Martini T, Di Mario C, Farb A, Finn AV, Galassi AR, Gibson CM, Hanratty C, Hill JM, Jaffer FA, Krucoff MW, Lombardi WL, Maelha A, Magee PFA, Mehran R, Moses JW, Nicholson WJ, Onuma Y, Sianos G, Sumitsuji S, Tsuchikane E, Virmani R, Walsh SJ, Werner GS, Yamane M, Stone GW, Rinfrat S, Stone GW (2021) Definitions and clinical trial design principles for coronary artery chronic total occlusion therapies: CTO-ARC consensus recommendations. *Circulation* 143(5):479–500
- Jeroudi OM, Alomar ME, Michael TT, El Sabbagh A, Patel VG, Mogabgab O, Fuh E, Sherbet D, Lo N, Roesle M, Rangan BV, Abdullah SM, Hastings JL, Grodin J, Banerjee S, Brilakis ES (2014) Prevalence and management of coronary chronic total occlusions in a tertiary Veterans Affairs hospital. *Catheter Cardiovasc Interv* 84(4):637–643
- Råmunddal T, Hoebers L, Henriques JPS, Dworeck C, Angerås O, Odenstedt J, Ioanes D, Olivecrona G, Harnek J, Jensen U, Aasa M, Jussila R, James S, Lagerqvist B, Matejka G, Albertsson P, Omerovic E (2014) Chronic total occlusions in Sweden: a report from the Swedish coronary angiography and angioplasty registry (SCAAR). *PLoS ONE* 9(8):e103850
- Azzalini L, Jolicoeur EM, Pighi M, Millán X, Picard F, Tadros VX, Fortier A, L'Allier PL, Ly HQ (2016) Epidemiology,

management strategies, and outcomes of patients with chronic total coronary occlusion. *Am J Cardiol* 118(8):1128–1135

5. Valenti R, Vergara R, Migliorini A, Parodi G, Carrabba N, Cerisano G, Dovellini EV, Antoniucci D (2013) Predictors of reocclusion after successful drug-eluting stent-supported percutaneous coronary intervention of chronic total occlusion. *J Am Coll Cardiol* 61(5):545–550
6. Walsh SJ, Hanratty CG, McEntegart M, Strange JW, Rigger J, Henriksen PA, Smith EJ, Wilson SJ, Hill JM, Mehmedbegovic Z, Chevalier B, Morice MC, Spratt JC (2020) Intravascular healing is not affected by approaches in contemporary CTO PCI: the CONSISTENT CTO study. *JACC Cardiovasc Interv* 13(12):1448–1457
7. Godino C, Latib A, Economou FI, Al-Lamee R, Ielasi A, Bassanelli G, Figini F, Chieffo A, Montorfano M, Colombo A, Carlini M (2012) Coronary chronic total occlusions. *Catheter Cardiovasc Interv* 79(1):20–27
8. Mahadevan K, Cosgrove C, Strange JW (2021) Factors influencing stent failure in chronic total occlusion coronary intervention. *Interv Cardiol* 12(16):e27
9. Li KHC, Wong KHG, Gong M, Liu T, Li G, Xia Y, Ho J, Nombela-Franco L, Sawant AC, Eccleshall S, Tse G, Vassiliou VS (2019) Percutaneous coronary intervention versus medical therapy for chronic total occlusion of coronary arteries: a systematic review and meta-analysis. *Curr Atheroscler Rep* 21(10):42
10. Alfonso F, Scheller B. State of the art: balloon catheter technologies – drug-coated balloon [Internet]. [cited 2024 Jun 5]. Available from: <https://eurointervention.pcronline.com/article/state-of-the-art-balloon-catheter-technologies-drug-coated-balloon>
11. Gunawardena TD, Corballis N, Merinopoulos I, Wickramarachchi U, Reinhold J, Maart C, Sreekumar S, Sawh C, Wistow T, Sarev T, Ryding A, Gilbert TJ, Clark A, Vassiliou VS, Eccleshall S (2023) Drug-Coated Balloon vs. drug-eluting stents for de novo unprotected left main stem disease: the SPARTAN-LMS study. *JCDD* 10(2):84
12. Merinopoulos I, Gunawardena T, Corballis N, Bhalraam U, Gilbert T, Maart C, Richardson P, Ryding A, Sarev T, Sawh C, Sulfi S, Wickramarachchi U, Wistow T, Mohamed MO, Mamas MA, Vassiliou VS, Eccleshall SC (2022) Paclitaxel drug-coated balloon-only angioplasty for de novo coronary artery disease in elective clinical practice. *Clin Res Cardiol*. <https://doi.org/10.1007/s00392-022-02106-y>
13. Merinopoulos I, Gunawardena T, Corballis N, Bhalraam U, Reinhold J, Wickramarachchi U, Maart C, Gilbert T, Richardson P, Sulfi S, Sarev T, Sawh C, Wistow T, Ryding A, Mohamed MO, Perperoglou A, Mamas MA, Vassiliou VS, Eccleshall SC (2023) Assessment of paclitaxel drug-coated balloon only angioplasty in STEMI. *JACC Cardiovasc Interv* 16(7):771–779
14. Merinopoulos I, Gunawardena T, Corballis N, Tsampasian V, Vassiliou V, Eccleshall S, Ryding A, Xydopoulos G (2023) Cost effectiveness analysis of drug coated balloon only angioplasty for de novo coronary artery disease. *Catheter Cardiovasc Interv* 102(6):987–996
15. Merinopoulos I, Bhalraam U, Kasmal B, Hewson D, Greenwood R, Eccleshall SC, Smith J, Tsampasian V, Vassiliou V (2024) Myocardial inflammation after elective percutaneous coronary intervention. *Hellenic J Cardiol* S1109–9666(24):00134–00139
16. Merinopoulos I, Bhalraam U, Holmes T, Tsampasian V, Corballis N, Gunawardena T, Sawh C, Maart C, Wistow T, Ryding A, Eccleshall SC, Smith J, Vassiliou VS (2023) Circulating intermediate monocytes CD14++CD16+ are increased after elective percutaneous coronary intervention. *PLoS ONE* 18(12):e0294746
17. Ottawa Hospital Research Institute [Internet]. [cited 2024 Jul 10]. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
18. Wang X, Yang X, Lu W, Pan L, Han Z, Pan S, Shan Y, Wang X, Zheng X, Li R, Zhu Y, Qin P, Shi Q, Zhou S, Zhang W, Guo S, Zhang P, Qin X, Sun G, Qin Z, Huang Z, Qiu C (2024) Long-term outcomes of less drug-eluting stents by the use of drug-coated balloons in de novo coronary chronic total occlusion intervention: a multicenter observational study. *Front Cardiovasc Med*. <https://doi.org/10.3389/fcvm.2023.1045859>
19. Qin Q, Chen L, Ge L, Qian J, Ma J, Ge J (2023) Long-term clinical outcomes of drug-coated balloon for the management of chronic total occlusions. *Coron Artery Dis* 34(8):555
20. Mehdi Madanchi M, Matthias Bossard M, Irena Majcen P, Giacomo M, Cioffi M, Francesco Ferraro M, Eleonora Gnan M, Varis Gjergjizi M, Yuan Zhi M, Vanessa Bade Bs, Mathias Wolfrum M, Federico Moccetti M, Stefan Toggweiler M, Adrian Attinger-Toller M, Florim Cuculi M. Outcomes Following Coronary Chronic Total Occlusion Revascularization With Drug-Coated Balloons. *Journal of Invasive Cardiology* [Internet]. 2024 Feb 21 [cited 2024 Jun 9];36(3). Available from: <https://www.hmpgloballearningnetwork.com/site/jic/original-contribution/outcomes-following-coronary-chronic-total-occlusion>
21. Basavarajaiah S, Mitomo S, Nakamura S, Sharma V, Mohammed I, Watanabe Y, Ouchi T, Bhatia G, Ment J, Athukorala S, Pitt M, Pulikal G, Freestone B, Rides H, Kumar N, Watkin R, Lee K (2021) Long-term outcome following percutaneous intervention of intra-stent coronary occlusion and evaluating the different treatment modalities. *IJC Heart Vasc* 1(34):100803
22. Zhang Y, Wu Z, Wang S, Liu T, Liu J (2023) Clinical outcome of paclitaxel-coated balloon angioplasty versus drug-eluting stent implantation for the treatment of coronary drug-eluting stent in-stent chronic total occlusion. *Cardiovasc Drugs Ther* 37(6):1155–1166
23. Kölner PJ, Scheller B, Liew HB, Rissanen TT, Ahmad WAW, Weser R, Hauschild T, Nuruddin AA, Clever YP, Ho HH, Kleber FX (2016) Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting: a feasibility and safety study. *Int J Cardiol* 15(225):262–267
24. Onishi T, Onishi Y, Kobayashi I, Umezawa S, Niwa A (2019) Drug-coated balloon angioplasty for de novo small vessel disease including chronic total occlusion and bifurcation in real-world clinical practice. *Cardiovasc Interv and Ther* 34(2):139–148
25. Onishi T, Onishi Y, Kobayashi I, Sato Y (2021) Late lumen enlargement after drug-coated balloon angioplasty for de novo coronary artery disease. *Cardiovasc Interv and Ther* 36(3):311–318
26. Jun EJ, Shin ES, Teoh EV, Bhak Y, Yuan SL, Chu CM, Garg S, Liew HB (2022) Clinical outcomes of drug-coated balloon treatment after successful revascularization of de novo chronic total occlusions. *Front Cardiovasc Med*. <https://doi.org/10.3389/fcvm.2022.821380>
27. Intraplaque wiring enables drug-coated balloons to be utilized for percutaneous recanalization of chronically occluded coronary arteries: Terashita: 2023—Catheterization and Cardiovascular Interventions - Wiley Online Library [Internet]. [cited 2024 Jun 9]. Available from: <https://onlinelibrary.wiley.com/doi/https://doi.org/10.1002/ccd.30596>
28. Ueno K, Morita N, Kojima Y, Takahashi H, Esaki M, Kondo H, Ando Y, Yamada M, Kosokabe T (2023) Serial quantitative angiographic study of target lumen enlargement after drug-coated balloon angioplasty for native coronary artery disease. *Catheter Cardiovasc Interv* 101(4):713–721
29. Funatsu A, Nakamura S, Inoue N, Nanto S, Nakamura M, Iwabuchi M, Ando K, Asano R, Habara S, Saito S, Kozuma K, Mitsudo K (2017) A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients with small vessel disease. *Clin Res Cardiol* 106(10):824–832

30. Kleber FX, Schulz A, Waliszewski M, Hauschild T, Böhm M, Dietz U, Cremers B, Scheller B, Clever YP (2015) Local paclitaxel induces late lumen enlargement in coronary arteries after balloon angioplasty. *Clin Res Cardiol* 104(3):217–225

31. Sogabe K, Koide M, Fukui K, Kato Y, Kitajima H, Akabame S, Zen K, Nakamura T, Matoba S (2021) Optical coherence tomography analysis of late lumen enlargement after paclitaxel-coated balloon angioplasty for de-novo coronary artery disease. *Catheter Cardiovasc Interv* 98(1):E35–42

32. Yamamoto T, Sawada T, Uzu K, Takaya T, Kawai H, Yasaka Y (2020) Possible mechanism of late lumen enlargement after treatment for de novo coronary lesions with drug-coated balloon. *Int J Cardiol* 15 (321):30–37

33. Brilakis ES, Mashayekhi K, Tsuchikane E, Rafeh NA, Alaswad K, Araya M, Avran A, Azzalini L, Babunashvili AM, Bayani B, Bhindi R, Boudou N, Boukhri M, Božinović NŽ, Bryniarski L, Bufo A, Buller CE, Burke MN, Büttner HJ, Cardoso P, Carlino M, Christiansen EH, Colombo A, Croce K, de Los SFD, Martini TD, Dens J, Mario CD, Dou K, Eged M, El-Guindy AM, Escaned J, Furkalo S, Gagnor A, Galassi AR, Garbo R, Ge J, Goel PK, Goktekin O, Grancini L, Grantham JA, Hanratty C, Harb S, Harding SA, Henriques JPS, Hill JM, Jaffer FA, Jang Y, Jussila R, Kalnins A, Kalyanasundaram A, Kandzari DE, Kao HL, Karmpaliotis D, Kassem HH, Knaapen P, Kornowski R, Krestyaninov O, Kumar AVG, Laanmets P, Lamelas P, Lee SW, Lefevre T, Li Y, Lim ST, Lo S, Lombardi W, Mc-Entegart M, Munawar M, Lecaro JAN, Ngo HM, Nicholson W, Olivcrona GK, Padilla L, Postu M, Quadros A, Quesada FH, Rao VSP, Reifart N, Saghatelyan M, Santiago R, Sianos G, Smith E, Spratt JC, Stone GW, Strange JW, Tammam K, Ungi I, Vo M, Vu VH, Walsh S, Werner GS, Wollmuth JR, Wu EB, Wyman RM, Xu B, Yamane M, Ybarra LF, Yeh RW, Zhang Q, Rinfret S (2019) Guiding principles for chronic total occlusion percutaneous coronary intervention. *Circulation*. <https://doi.org/10.1161/CIRCULATIONAHA.119.039797>

34. El Shafey WEDH (2017) Pattern of vascular remodeling of distal reference segment after recanalization of chronic total occlusion, long-term angiographic follow-up Egypt. *Heart J* 69(2):161–163

35. Spratt JC, Hanratty CG, Walsh SJ, Wilson SJ (2019) A Guide to Mastering Antegrade CTO PCI. Newcastle Upon Tyne: Optima Education

36. Kato M, Kimura T, Morimoto T, Nishikawa H, Uchida F, Suzuki H, Hayashi Y, Kadota K, Mitsudo K (2012) Comparison of five-year outcome of sirolimus-eluting stent implantation for chronic total occlusions versus for non-chronic total occlusion (from the j-Cypher Registry). *Am J Cardiol* 110(9):1282–1289

37. Mehran R, Claeussen BE, Godino C, Dangas GD, Obunai K, Kanwal S, Carlino M, Henriques JPS, Di Mario C, Kim YH, Park SJ, Stone GW, Leon MB, Moses JW, Colombo A (2011) Long-term outcome of percutaneous coronary intervention for chronic total occlusions. *JACC Cardiovasc Intervent* 4(9):952–961

38. Kwon O, Lee PH, Lee SW, Brilakis ES, Lee JY, Yoon YH, Lee K, Park H, Kang SJ, Kim YH, Lee CW, Park SW (2021) Clinical outcomes of post-stent intravascular ultrasound examination for chronic total occlusion intervention with drug-eluting stents. *EuroIntervention* 17(8):e639–e646

39. Zivelonghi C, Agostoni P, Teeuwen K, Van der SRJ, Henriques JPS, Vermeersch PHMJ, Bosschaert MAR, Kelder JC, Tijssen JGP, Suttorp MJ (2019) 3-year clinical outcomes of the PRISON-IV trial. *JACC Cardiovasc Intervent* 12(17):1747–1749

40. Werner GS, Martin-Yuste V, Hildick-Smith D, Boudou N, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J, di Mario C, Hovasse T, Teruel L, Bufo A, Lauer B, Bogaerts K, Goicolea J, Spratt JC, Gershlick AH, Galassi AR, Louvard Y, EUROCTO trial investigators (2018) A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions. *Eur Heart J* 39(26):2484–2493

41. Werner G, Hildick-Smith D, Martin-Yuste V, Boudou N, Sianos G, Gelev V, Rumoroso JR, Erglis A, Christiansen EH, Escaned J, Mario CD, Teruel L, Bufo A, Lauer B, Galassi AR, Louvard Y. Three-year outcomes of A Randomized Multicentre Trial Comparing Revascularization and Optimal Medical Therapy for Chronic Total Coronary Occlusions (EuroCTO) [Internet]. [cited 2024 Jul 11]. Available from: <https://eurointervention.pronline.com/article/three-year-outcomes-of-eurocto-a-randomized-multicentre-trial-comparing-revascularization-and-optimal-medical-therapy-for-chronic-total-coronary-occlusions>

42. Ae A, Sd B, Sr D, J B, Cl G, Ww O. Success, safety, and mechanisms of failure of percutaneous coronary intervention for occlusive non-drug-eluting in-stent restenosis versus native artery total occlusion. *The American journal of cardiology* [Internet]. 2005 Jun 15 [cited 2024 Jun 19];95(12). Available from: <https://pubmed.ncbi.nlm.nih.gov/15950572/>

43. Wang Y, Jie HA, Luan B, Jiao ZX, Yu LZ, Yang PX (2023) Prevalence, predictors, and management for balloon uncrossable or undilatable lesions in patients undergoing percutaneous coronary intervention with in-stent restenosis chronic total occlusion. *Front Cardiovasc Med*. <https://doi.org/10.3389/fcvm.2023.1095960>

44. L A, R D, S O, S B, B B, F G, J C, M P, M C, A C, S R. Procedural and Long-Term Outcomes of Percutaneous Coronary Intervention for In-Stent Chronic Total Occlusion. *JACC Cardiovascular interventions* [Internet]. 2017 May 8 [cited 2024 Jun 19];10(9). Available from: <https://pubmed.ncbi.nlm.nih.gov/28412256/>

45. Lee SH, Cho JY, Kim JS, Lee HJ, Yang JH, Park JH, Hong SJ, Choi RK, Choi SH, Gwon HC, Lim DS, Yu CW (2020) A comparison of procedural success rate and long-term clinical outcomes between in-stent restenosis chronic total occlusion and de novo chronic total occlusion using multicenter registry data. *Clin Res Cardiol* 109(5):628–637

46. H Y, H K, Y F, S T, T H, M T, T A, H O, A N, T W, Y W, T Y, S M, T S, T N, H I, N K, S N, K H, S N. Clinical Outcomes of Drug-Eluting Balloon for In-Stent Restenosis Based on the Number of Metallic Layers. *Circulation Cardiovascular interventions* [Internet]. 2018 Aug [cited 2024 Jun 19];11(8). Available from: <https://pubmed.ncbi.nlm.nih.gov/30354780/>

47. Jun E, Shin ES, Kim B, Teoh EV, Chu CM, Kim S, Liew H (2023) Coronary artery aneurysm formation after paclitaxel-coated balloon-only intervention for de novo coronary chronic total occlusion. *Front Cardiovasc Med* 4:9

48. Levin AD, Vukmirovic N, Hwang CW, Edelman ER (2004) Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. *Proc Natl Acad Sci U S A* 101(25):9463–9467

49. Creel CJ, Lovich MA, Edelman ER (2000) Arterial paclitaxel distribution and deposition. *Circ Res* 86(8):879–884

50. Ybarra LF, Dandona S, Daneault B, Rinfret S (2020) Drug-coated balloon after subintimal plaque modification in failed coronary chronic total occlusion percutaneous coronary intervention: a novel concept. *Catheter Cardiovasc Interv* 96(3):609–613

51. Xenogiannis I, Choi JW, Alaswad K, Khatri JJ, Doing AH, Dattilo P, Jaffer FA, Uretsky B, Krestyaninov O, Khelimskii D, Patel M, Mahmud E, Potluri S, Koutouzis M, Tsiafoutis I, Jaber W, Samady H, Jefferson BK, Patel T, Megaly MS, Hall AB, Vemou E, Nikolakopoulos I, Rangan BV, Abdullah S, Garcia S, Banerjee S, Burke MN, Brilakis ES (2020) Outcomes

of subintimal plaque modification in chronic total occlusion percutaneous coronary intervention. *Catheter Cardiovasc Interv* 96(5):1029–1035

52. Amat-Santos IJ, Marengo G, Ybarra LF, Fernández-Díaz JA, Regueiro A, Gutiérrez A, Martín-Moreiras J, Sánchez-Luna JP, González-Gutiérrez JC, Fernandez-Cordon C, Carrasco-Moraleja M, Rinfret S. Drug-coated versus conventional balloons to improve recanalization of a coronary chronic total occlusion after failed attempt [Internet]. medRxiv; 2023 [cited 2025 Mar 14]. p. 2023.07.10.23292478. Available from: <https://www.medrxiv.org/content/https://doi.org/10.1101/2023.07.10.23292478v1>

53. Amat-Santos IJ, Marengo G, Ybarra LF, Fernández-Díaz JA, Regueiro A, Gutiérrez A, Martín-Moreiras J, Sánchez-Luna JP, González-Gutiérrez JC, Fernandez-Cordon C, Carrasco-Moraleja M, Rinfret S (2024) Drug-coated versus conventional balloons to improve recanalization of a coronary chronic total occlusion after failed attempt: the improved-CTO registry. *J Interv Cardiol* 2024(1):2797561